European Biotechnology Magazine

Windward raises $175M in IPO, adds $50M from Sanofi

Swiss biotech Windward Bio Group has priced its Nasdaq IPO at $17 per share, setting it up to raise $175 million (€158 million) from public investors and another $50 million (€45 million) through … more ➔

The Leadership Edit Thumbnail European Biotechnology

Appointments

Gubra’s board replaces CEO; Commit staffs its first drug program; TECregen names CMO

Every Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: Gubra fires its CEO, Commit strengthens … more ➔

cancer research

Orakl raises $34M to scale AI platform predicting cancer drug responses

Paris-based Orakl Oncology has raised an oversubscribed $34 million (€31 million) Series A, co-led by Swedish investor Norrsken VC and French venture firm Singular, to expand its platform combining … more ➔

fundraising

Addex spinout Neurosterix raises $105M to advance schizophrenia drug into Phase 2

Neurosterix, a spinout of Swiss biotech Addex Therapeutics, has raised $105 million (about €94 million) to advance its lead schizophrenia drug into Phase 2 clinical development. The Boston- and Geneva-based … more ➔

small molecule

Lakefront abandons Galapagos-developed TYK2 inhibitor after unsuccessful partnering efforts

Belgian biotech Lakefront Biotherapeutics, formerly Galapagos, has discontinued its oral TYK2 inhibitor GLPG3667 after analyzing the drug’s competitive landscape and holding talks with potential partners. … more ➔

European Biotechnology

1 / 4

The autumn issue of European Biotechnology magazine asks what happens when biotech leaves Earth. Our cover story explores how microgravity could help researchers study disease, improve drug formulations … more ➔

Get a free sample copy | Abo

2 / 4

The summer issue of European Biotechnology Magazine showcases the latest developments in drug delivery and RNA technologies. This issue features a list of eight venture capital firms to watch in 2026. … more ➔

Get a free sample copy | Abo

3 / 4

The Spring 2026 issue of European Biotechnology Magazine presents a list of start-ups to watch in 2026 and explores other fascinating topics such as: Can biotechnology finally fix infertility? Can … more ➔

Get a free sample copy | Abo

4 / 4

Europe is losing much of its expertise in deep tech and life sciences to the US. To prevent another generation of innovation from being lost, Europe must close the funding gaps. more ➔

Get a free sample copy | Abo

Stay up to date with the biotech industry!

Once a week, european-biotechnology.com brings you up to date on the latest developments in the biotech industry. In our free newsletter, you will find the latest news from business, research and politics, as well as lots of useful information and job vacancies.

Subscribe to our free newsletter!Subscribe here

fundraising

VectorY secures €74.5M to advance ALS gene therapy trial

Amsterdam-based VectorY Therapeutics has secured €74.5 million ($83.5 million) in new financing to advance its lead gene therapy candidate for amyotrophic lateral sclerosis (ALS) and expand its pipeline … more ➔

startup

SRTD raises €31.5M seed round to develop cell-selective RNA therapies

Germany-based biotech company SRTD Biotech has closed a €31.5 million seed funding round. At the heart of its approach is an RNA technology designed to address a fundamental challenge facing many RNA-based … more ➔

APPOINTMENTS

all appointments

Spica Therapeutics

Boehringer-Zealand obesity drug clears cardiovascular safety hurdle, but tolerability concerns remain

German drugmaker Boehringer Ingelheim and Denmark’s Zealand Pharma have reported positive Phase 3 results for their experimental obesity drug survodutide, which met its primary cardiovascular safety … more ➔

fundraising

Oyster Therapeutics raises $60M to bring Alzheimer’s tau degrader to clinic

London-based Kesmalea Therapeutics has raised $60 million (about €53.5 million) in a Series A-2 financing and rebranded as Oyster Therapeutics. The funding will support the development of an oral, … more ➔

All news

EVENT

November 23 - November 25in Darmstadt

PharmaLab Congress and Exhibition 2026 at a new venue

The event for all pharmaceutical laboratory sectors will continue its success story for the 14th time on 23-25 November 2026 - now at a new venue in Darmstadt (near Frankfurt Airport): the darmstadtium, a modern conference centre with state-of-the-art and sustainable technical facilities. ➔

Windward raises $175M in IPO, adds $50M from Sanofi

Gubra’s board replaces CEO; Commit staffs its first drug program; TECregen names CMO

Orakl raises $34M to scale AI platform predicting cancer drug responses

Addex spinout Neurosterix raises $105M to advance schizophrenia drug into Phase 2

Lakefront abandons Galapagos-developed TYK2 inhibitor after unsuccessful partnering efforts

European Biotechnology

NEWSLETTER

Stay up to date with the biotech industry!

VectorY secures €74.5M to advance ALS gene therapy trial

SRTD raises €31.5M seed round to develop cell-selective RNA therapies

Sponsored Publications

Austria builds life sciences momentum

CDMO: How to find a reliable partner

APPOINTMENTS

New CEO for the next level

New CEO took over the reins

Samanta Cimitan to (re)join Lonza from Celonic

Clinical Development Expert has started

Swiss VC Redalpine closes eighth fund at $250 million

Boehringer-Zealand obesity drug clears cardiovascular safety hurdle, but tolerability concerns remain

Oyster Therapeutics raises $60M to bring Alzheimer’s tau degrader to clinic

EVENT

PharmaLab Congress and Exhibition 2026 at a new venue

Stay up to date every week with the european biotechnology newsletter.

Stay up to date every week with the european biotechnology newsletter.

European Biotechnology

NEWSLETTER

Stay up to date with the biotech industry!

Sponsored Publications

EVENT

PharmaLab Congress and Exhibition 2026 at a new venue